GlaxoSmithKline Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹2,550.80(-1.99%)November 7, 2025 14:36:31 PM IST
- NSE
- BSE
- Vol : 138.54K (NSE + BSE)Last 20 day avg : 64.34 K
GlaxoSmithKline Pharmaceuticals is trading -1.99% lower at Rs 2,550.80 as compared to its last closing price. GlaxoSmithKline Pharmaceuticals has been trading in the price range of 2,597.55 & 2,480.00. GlaxoSmithKline Pharmaceuticals has given 15.70% in this year & -1.41% in the last 5 days. GlaxoSmithKline Pharmaceuticals has TTM P/E ratio 47.17 as compared to the sector P/E of 23.79.There are 4 analysts who have initiated coverage on GlaxoSmithKline Pharmaceuticals. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 257.49 Crores in its last quarter.Listed peers of GlaxoSmithKline Pharmaceuticals include Abbott India (-2.02%), Alkem Laboratories (0.27%), Glaxosmithkline Pharmaceutical (-1.99%).The Mutual Fund holding in GlaxoSmithKline Pharmaceuticals was at 5.00% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in GlaxoSmithKline Pharmaceuticals was at 5.00% in 30 Sep 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 07, 2025, 09:08 AM UTC
- BetaLow volatility0.30Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.61Annual dividends as a percentage of the stock price.
- P/BHigher than historical values22.62The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values46.21Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.34The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during June quarter by 1.16% from Rs 814.65 crore to Rs 805.17 crore, year-on-year- The company has grown its June quarter profit by 12.44% from Rs 182.33 crore to Rs 205.01 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,734.33
- R2
- 2,783.27
- R3
- 2,868.93
- S1
- 2,599.73
- S2
- 2,514.07
- S3
- 2,465.13
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Abbott India | Bearish | 28,883.65 | -2.02 | 61,375.74 | 53.21 | 17.78 | 1.34 | 3.73 |
| Alkem Laboratories | Bullish | 5,658.75 | 0.27 | 67,822.28 | 26.62 | 4.81 | 0.93 | 4.83 |
| Glaxosmithkline Pharmaceutical | Bearish | 2,550.80 | -1.99 | 43,261.13 | 60.53 | 28.67 | 1.27 | 0.13 |
| Glenmark Pharmaceuticals | Moderately Bearish | 1,815.60 | 0.27 | 51,236.38 | 37.95 | 5.69 | 0.14 | 7.90 |
| Biocon | Bullish | 381.35 | -0.95 | 50,985.11 | 47.70 | 2.08 | 0.13 | 59.81 |
- Promoter(s) holds a high stake in the company at 75.00%
- FIIs are invested in this company
- FIIs holding has increased by 0.11 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.17 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
| 2025-02-10 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE159A01016
- BSE Code500660
- NSE CodeGLAXO
GlaxoSmithKline Pharmaceuticals is trading at 2550.80 as on Fri Nov 07 2025 09:06:31. This is -1.99% lower as compared to its previous closing price of 2602.70.
The market capitalization of GlaxoSmithKline Pharmaceuticals is 43261.13 Cr as on Fri Nov 07 2025 09:06:31.
The average broker rating on GlaxoSmithKline Pharmaceuticals is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 1 analysts have given a hold rating
- 1 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for GlaxoSmithKline Pharmaceuticals is 3515.95 whereas the 52 wk low is 1924.30
GlaxoSmithKline Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 47.17
- Sector P/E: 23.79
- Dividend Yield: 1.61%
- D/E ratio: 0.02
GlaxoSmithKline Pharmaceuticals reported a net profit of 927.58 Cr in 2025.
The Mutual Fund Shareholding was 5.00% at the end of 30 Sep 2025.